ALKBH5 and hepatocellular carcinoma: The results suggest HBV may hijacks the epitranscriptomics enzyme ALKBH5 to induce HCC through the HBx-ALKBH5 positive feedback, which might represent a novel therapeutic target of HBV-HCC.